Pluta, Andrzej
Mayo Clinic
Department of Hematological Oncology, Oncology Spec. Hospital, Brzozow, Poland;
Citations 2
Efficacy and safety of ixazomib plus lenalidomide-dexamethasone (IRd) vs placebo-rd in patients (pts) with relapsed/refractory multiple myeloma (RRMM) by cytogenetic risk status in the global phase III Tourmaline-MM1 study.
Richardson, Paul G. , Palumbo, Antonio , Viterbo, Luísa, Nagler, Arnon , Yehuda, Dina Ben , Pour, Luděk, Langer, Christian , Pluta, Andrzej, Berg, Deborah, Velde, Helgi van de , Esseltine, Dixie-Lee, Bacco, Alessandra Di , Richardson, Paul Gerard Guy , Avet‐Loiseau, Hervé , Ganly, Peter S. , Miguel, Jesús F. San , Rajkumar, S. Vincent , Bahlis, Nizar Jacques , Masszi, Tamás , Lin, Jianchang , Esseltine, Dixie‐Lee, Moreau, Philippe
Journal of Clinical Oncology | September 6, 2018 | Volume: 34 | Issue: 15_suppl | Pages: 8018-8018
Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients
Avet‐Loiseau, Hervé , Masszi, Tamás , Viterbo, Luísa, Pour, Luděk, Palumbo, Antonio , Cavo, Michèle , Langer, Christian , Pluta, Andrzej, Nagler, Arnon , Kumar, Shaji , Ben‐Yehuda, Dina, Miguel, Jesús F. San , Berg, Deborah, Lin, Jianchang , Velde, Helgi van de , Esseltine, Dixie‐Lee, Bacco, Alessandra Di , Moreau, Philippe , Richardson, Paul G. , Moreau, Philippe , San-Miguel, Jesus , Masszi, Tamas , Bahlis, Nizar Jacques , Chng, Wee Joo , Ganly, Peter S. , Rajkumar, S. Vincent , Esseltine, Dixie‐Lee, Richardson, Paul Gerard Guy
Blood | October 20, 2017 | Volume: 130 | Issue: 24 | Pages: 2610-2618
Key Points IRd was associated with a consistent PFS benefit vs placebo-Rd in RRMM patients with high-risk and standard-risk cytogenetics. The addition of ixazomib to Rd overcomes the poor PFS associated with high-risk cytogenetics in patients with RRMM.